NCT03972397

Brief Summary

The purpose of the study is to assess the efficacy of intercostal nerve cryoablation on the magnitude and duration of postoperative pain control both in patients undergoing thoracoabdominal incisions for the descending or thoracoabdominal aortic aneurysm repair.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jul 2019

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 30, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 3, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

July 15, 2019

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 22, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 22, 2022

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

November 2, 2023

Completed
Last Updated

November 2, 2023

Status Verified

October 1, 2023

Enrollment Period

3.2 years

First QC Date

May 30, 2019

Results QC Date

September 22, 2023

Last Update Submit

October 31, 2023

Conditions

Keywords

Cryoablation

Outcome Measures

Primary Outcomes (18)

  • Score on Numeric Pain Scale (NPS)

    The NPS measures the intensity of pain. The total score ranges from 0 to 10, with 0 being no pain and 10 the highest pain.

    post-operative day 5

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    baseline

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    post-operative day 3

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    post-operative day 4

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    post-operative day 5

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    post-operative day 30

  • Brief Pain Inventory (BPI) - Severity Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The total severity score ranges from 0 to 10, with 0 indicating no pain and 10 indicating pain as bad as you can imagine.

    post-operative day 180

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    baseline

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    post-operative day 3

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    post-operative day 4

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    post-operative day 5

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    post-operative day 30

  • Brief Pain Inventory (BPI) - Pain Interference Score

    The Brief Pain Inventory is a medical questionnaire used to measure pain, developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. The pain interference score indicates how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. The total pain interference score ranges from 0 to 10, with 0 indicating no interference and 10 indicating complete interference.

    post-operative day 180

  • 5-point Satisfaction Scale

    The 5-point satisfaction scale assesses post-surgical analgesia satisfaction. The total score ranges from 1 to 5, with 1 being "very dissatisfied" and 5 being "very satisfied".

    post-operative day 3

  • 5-point Satisfaction Scale

    The 5-point satisfaction scale assesses post-surgical analgesia satisfaction. The total score ranges from 1 to 5, with 1 being "very dissatisfied" and 5 being "very satisfied".

    post-operative day 4

  • 5-point Satisfaction Scale

    The 5-point satisfaction scale assesses post-surgical analgesia satisfaction. The total score ranges from 1 to 5, with 1 being "very dissatisfied" and 5 being "very satisfied".

    post-operative day 5

  • 5-point Satisfaction Scale

    The 5-point satisfaction scale assesses post-surgical analgesia satisfaction. The total score ranges from 1 to 5, with 1 being "very dissatisfied" and 5 being "very satisfied".

    post-operative day 30

  • 5-point Satisfaction Scale

    The 5-point satisfaction scale assesses post-surgical analgesia satisfaction. The total score ranges from 1 to 5, with 1 being "very dissatisfied" and 5 being "very satisfied".

    post-operative day 180

Secondary Outcomes (7)

  • Total Amount in mg of Opioid Medication Consumed

    third to fifth post-operative days after surgery

  • Number of Participants Who Require of Opioids at the Time of Discharge

    at the time of discharge (about a week after surgery)

  • Number of Participants Who Utilize Patient-controlled Analgesia (PCA)

    from the time immediately after surgery to post-operative day 3

  • Amount of Patient-controlled Analgesia (PCA) Used

    from the time immediately after surgery to post-operative day 3

  • Number of Participants Who Attain Physical Therapy Goal That Justifies Discharge From Inpatient Physical Therapy Within 72 Hours

    72 hours after surgery

  • +2 more secondary outcomes

Study Arms (2)

Intercostal Nerve Cryoablation plus SOC Pain Control

EXPERIMENTAL

Standard of Care (SOC)

Device: Intercostal Nerve CryoablationDrug: Bupivacaine liposomal injectable suspensionDrug: Patient-controlled analgesia (PCA)

Standard of Care (SOC) Pain Control

ACTIVE COMPARATOR
Drug: Bupivacaine liposomal injectable suspensionDrug: Patient-controlled analgesia (PCA)

Interventions

Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.

Also known as: CryoICE® CRYO2 cryoablation probes (AtriCure, Inc)
Intercostal Nerve Cryoablation plus SOC Pain Control

Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).

Also known as: Exparel® (Pacira Pharmacoceuticals)
Intercostal Nerve Cryoablation plus SOC Pain ControlStandard of Care (SOC) Pain Control

Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.

Intercostal Nerve Cryoablation plus SOC Pain ControlStandard of Care (SOC) Pain Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Descending/thoracoabdominal incision is planned
  • There is reasonable expectation that the patient will be extubated within 48 hours after surgery

You may not qualify if:

  • The patient has a known allergy to morphine or any opioid
  • The patient has a known chronic pain disorder or takes daily opioid medication \> 1 month prior to surgery
  • The surgeon/anesthesiologist concludes that the period for intubation will be likely be for more than 48 hours after surgery There is anticipated difficulty communicating pain status due to language or other barriers at the investigator discretion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Analgesia, Patient-Controlled

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnalgesiaAnesthesia and Analgesia

Results Point of Contact

Title
Anthony L Estrera, MD
Organization
The University of Texas Health Science Center at Houston

Study Officials

  • Anthony L Estrera, MD

    The University of Texas Health Science Center, Houston

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 30, 2019

First Posted

June 3, 2019

Study Start

July 15, 2019

Primary Completion

September 22, 2022

Study Completion

September 22, 2022

Last Updated

November 2, 2023

Results First Posted

November 2, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations